References
- The World Health Organization. Depression and other common mental disorders: global health estimates. Geneva. 2017
- Wiles N, Thomas L, Abel A, et al. Cognitive behavioural therapy as an adjunct to pharmacotherapy for primary care based patients with treatment resistant depression: results of the CoBalT randomised controlled trial. Lancet [Internet]. 2013 Feb 2 [cited 2018 Oct 10];381(9864):375–384.
- Johnston KM, Powell LC, Anderson IM, et al. The burden of treatment-resistant depression: a systematic review of the economic and quality of life literature. Vol. 242, Journal of Affective Disorders. Elsevier B.V.; 2019. p. 195–210.
- Tanner JA, Hensel J, Davies PE, et al. Economic burden of depression and associated resource use in Manitoba, Canada. Can J Psychiatry [Internet]. 2020 May 1 [cited 2020 Dec 21];65(5):338–346. Available from: https://pubmed-ncbi-nlm-nih-gov.myaccess.library.utoronto.ca/31835904/
- Association AP Diagnostic and statistical manual of mental disorders: DSM-5. 2013 [cited 2020 Apr 22]; Available from: https://www.academia.edu/download/38718268/CSL6820_21.pdf
- The WHO ICD-10 classification of mental and behavioural disorders clinical descriptions and diagnostic guidelines World Health Organization [Internet]. [cited 2018 Oct 10]. Available from: http://www.who.int/classifications/icd/en/bluebook.pdf
- McIntyre RS, Filteau M-J, Martin L, et al. Treatment-resistant depression: definitions, review of the evidence, and algorithmic approach. J Affect Disord [Internet]. 2014 Mar 1;156:1–7. Available from: http://myaccess.library.utoronto.ca/login?url=https://search.proquest.com/docview/1518033121?accountid=14771
- Brown S, Rittenbach K, Cheung S, et al. Current and common definitions of treatment-resistant depression: findings from a systematic review and qualitative interviews [Internet]. Vol. 64, Canadian Journal of Psychiatry. SAGE Publications Inc.; 2019 [cited 2021 Jan 6]. 380–387. Available from: http://journals.sagepub.com/doi/10.1177/0706743719828965
- Gaynes BN, Lux L, Gartlehner G, et al. Defining treatment‐resistant depression. Depress Anxiety [Internet]. 2020 Feb 22 [cited 2021 Jan 6];37(2):134–145. Available from: https://onlinelibrary.wiley.com/doi/abs/10.1002/da.22968
- Akil H, Gordon J, Hen R, et al. Treatment resistant depression: a multi-scale, systems biology approach [Internet]. Vol. 84, Neuroscience and Biobehavioral Reviews. Elsevier Ltd; 2018 [cited 2021 Jan 6]. p. 272–288. Available from: https://pubmed.ncbi.nlm.nih.gov/28859997/
- Athira KV, Bandopadhyay S, Samudrala PK, et al. An overview of the heterogeneity of major depressive disorder: current knowledge and future prospective. Curr Neuropharmacol. 2019 Oct 1;18(3):168–187.
- Strawbridge R, Young AH, Cleare AJ Biomarkers for depression: recent insights, current challenges and future prospects. Vol. 13, Neuropsychiatric Disease and Treatment. Dove Medical Press Ltd.; 2017. p. 1245–1262.
- Bartova L, Dold M, Kautzky A, et al. Results of the European Group for the Study of Resistant Depression (GSRD) — basis for further research and clinical practice. Vol. 20, World Journal of Biological Psychiatry. Taylor and Francis Ltd; 2019. p. 427–448.
- Insel TR, Cuthbert BN. Brain disorders? Precisely: precision medicine comes to psychiatry. Science (80-) [Internet]. 2015 May 1 [cited 2020 Dec 21];348(6234):499–500. Available from: https://pubmed-ncbi-nlm-nih-gov.myaccess.library.utoronto.ca/25931539/
- Lin E, Kuo PH, Liu YL, et al. Prediction of antidepressant treatment response and remission using an ensemble machine learning framework. Pharmaceuticals [Internet]. 2020 Oct 1 [cited 2020 Dec 21];13(10):1–12. Available from: https://pubmed-ncbi-nlm-nih-gov.myaccess.library.utoronto.ca/33065962/
- Perlman K, Benrimoh D, Israel S, et al. A systematic meta-review of predictors of antidepressant treatment outcome in major depressive disorder [Internet]. Vol. 243, Journal of Affective Disorders. Elsevier B.V.; 2019 [cited 2020 Dec 21]. p. 503–515. Available from: https://pubmed-ncbi-nlm-nih-gov.myaccess.library.utoronto.ca/30286415/
- Lee Y, Ragguett RM, Mansur RB, et al. Applications of machine learning algorithms to predict therapeutic outcomes in depression: a meta-analysis and systematic review [Internet]. Vol. 241, Journal of Affective Disorders. Elsevier B.V.; 2018 [cited 2020 Dec 21]. p. 519–532. Available from: https://pubmed-ncbi-nlm-nih-gov.myaccess.library.utoronto.ca/30153635/
- Bzdok D, Meyer-Lindenberg A. Machine learning for precision psychiatry: opportunities and challenges [Internet]. Vol. 3, Biological Psychiatry: Cognitive Neuroscience and Neuroimaging. Elsevier Inc; 2018 [cited 2020 Dec 21]. p. 223–230. Available from: https://pubmed-ncbi-nlm-nih-gov.myaccess.library.utoronto.ca/29486863/
- Manchia M, Pisanu C, Squassina A, et al. Challenges and future prospects of precision medicine in psychiatry [Internet]. Vol. 13, Pharmacogenomics and Personalized Medicine. Dove Medical Press Ltd; 2020 [cited 2020 Dec 21]. p. 127–140. Available from: https://pubmed-ncbi-nlm-nih-gov.myaccess.library.utoronto.ca/32425581/
- Hedderich DM, Eickhoff SB Machine learning for psychiatry: getting doctors at the black box? [Internet]. Molecular Psychiatry. Springer Nature; 2020 [cited 2020 Dec 21]. Available from: https://pubmed-ncbi-nlm-nih-gov.myaccess.library.utoronto.ca/33173196/
- Ermers NJ, Hagoort K, Scheepers FE. The predictive validity of machine learning models in the classification and treatment of major depressive disorder: state of the art and future directions. Front Psychiatry [Internet]. 2020 May 25 [cited 2020 Dec 21];11. Available from: https://pubmed-ncbi-nlm-nih-gov.myaccess.library.utoronto.ca/32523557/
- Pastorino R, De Vito C, Migliara G, et al. Benefits and challenges of big data in healthcare: an overview of the European initiatives. Eur J Public Health. 2019 Oct 1;29(Supplement_3):23–27.
- Mulsant BH, Blumberger DM, Ismail Z, et al. A systematic approach to pharmacotherapy for geriatric major depression [Internet]. Vol. 30, Clinics in Geriatric Medicine. W.B. Saunders; 2014 [cited 2020 Dec 21]. p. 517–534. Available from: https://pubmed-ncbi-nlm-nih-gov.myaccess.library.utoronto.ca/25037293/
- Bollini P, Pampallona S, Tibaldi G, et al. Effectiveness of antidepressants. Meta-analysis of dose-effect relationships in randomised clinical trials [Internet]. Vol. 174, British Journal of Psychiatry. Royal College of Psychiatrists; 1999 [cited 2020 Dec 21]. p. 297–303. Available from: https://pubmed-ncbi-nlm-nih-gov.myaccess.library.utoronto.ca/10533547/
- Jakubovski E, Varigonda AL, Freemantle N, et al. Systematic review and meta-analysis: dose-response relationship of selective serotonin reuptake inhibitors in major depressive disorder [Internet]. Vol. 173, American Journal of Psychiatry. American Psychiatric Association; 2016 [cited 2020 Dec 21]. p. 174–183. Available from: https://pubmed-ncbi-nlm-nih-gov.myaccess.library.utoronto.ca/26552940/
- Furukawa TA, Cipriani A, Cowen PJ, et al., Optimal dose of selective serotonin reuptake inhibitors, venlafaxine, and mirtazapine in major depression: a systematic review and dose-response meta-analysis. Lancet Psychiatry [Internet]. 2019 Jul 1 [cited 2020 Dec 21];6(7):601–609. Available from: https://pubmed-ncbi-nlm-nih-gov.myaccess.library.utoronto.ca/31178367/
- Ruhe HG, Booij J, van Weert HC, et al. Dose-escalation of SSRIS in major depressive disorder. Should not be recommended in current guidelines. PubMed Tijdschr Psychiatr [Internet]. 2009 [cited 2020 Dec 21];52(9):615–625. Available from: https://pubmed-ncbi-nlm-nih-gov.myaccess.library.utoronto.ca/20862644/
- Meyer JH, Wilson AA, Sagrati S, et al. Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study. Am J Psychiatry [Internet]. 2004 May [cited 2020 Dec 21];161(5):826–835. Available from: https://pubmed-ncbi-nlm-nih-gov.myaccess.library.utoronto.ca/15121647/
- Adli M, Baethge C, Heinz A, et al. Is dose escalation of antidepressants a rational strategy after a medium-dose treatment has failed? A systematic review. Eur Arch Psychiatry Clin Neurosci [Internet]. Vol. 255, ; 2005 [cited 2020 Dec 21]. p. 387–400. Available from: https://pubmed-ncbi-nlm-nih-gov.myaccess.library.utoronto.ca/15868067/
- Rink L, Braun C, Bschor T, et al. Dose increase versus unchanged continuation of antidepressants after initial antidepressant treatment failure in patients with major depressive disorder: a systematic review and meta-analysis of randomized, double-blind trials. J Clin Psychiatry [Internet]. 2018 May 1 [cited 2020 Dec 21];79(3). Available from: https://pubmed-ncbi-nlm-nih-gov.myaccess.library.utoronto.ca/29873954/
- Garcia-Toro M, Medina E, Galan JL, et al. Treatment patterns in major depressive disorder after an inadequate response to first-line antidepressant treatment. BMC Psychiatry [Internet]. 2012 Sep 18 [cited 2020 Dec 21];12(1). Available from: https://pubmed-ncbi-nlm-nih-gov.myaccess.library.utoronto.ca/22988986/
- Saragoussi D, Chollet J, Bineau S, et al. Antidepressant switching patterns in the treatment of major depressive disorder: a General Practice Research Database (GPRD) study. Int J Clin Pract [Internet]. 2012 Nov [cited 2020 Dec 21];66(11):1079–1087. Available from: : https://pubmed-ncbi-nlm-nih-gov.myaccess.library.utoronto.ca/23067031/
- Mars B, Heron J, Gunnell D, et al. Prevalence and patterns of antidepressant switching amongst primary care patients in the UK. J Psychopharmacol [Internet]. 2017 May 1 [cited 2020 Dec 21];31(5):553–560. Available from: https://pubmed-ncbi-nlm-nih-gov.myaccess.library.utoronto.ca/28460603/
- Ruhé HG, Huyser J, Swinkels JA, et al. Switching antidepressants after a first selective serotonin reuptake inhibitor in major depressive disorder: a systematic review [Internet]. 67, Journal of Clinical Psychiatry. Physicians Postgraduate Press Inc.; 2006 [cited 2020 Dec 21]. 1836–1855. Available from: https://pubmed-ncbi-nlm-nih-gov.myaccess.library.utoronto.ca/17194261/
- Papakostas GI, Fava M, Thase ME, Treatment of SSRI-resistant depression: a meta-analysis comparing within- versus across-class switches. Biol Psychiatry [Internet]. 2008 Apr 1 [cited 2020 Dec 21];63(7):699–704. Available from: https://pubmed-ncbi-nlm-nih-gov.myaccess.library.utoronto.ca/17919460/
- Bschor T, Kilarski LL Are antidepressants effective? A debate on their efficacy for the treatment of major depression in adults [Internet]. 16, Expert Review of Neurotherapeutics. Taylor and Francis Ltd; 2016 [cited 2020 Dec 21]. 367–374. Available from: https://pubmed-ncbi-nlm-nih-gov.myaccess.library.utoronto.ca/26891111/
- Bschor T, Kern H, Henssler J, et al., Switching the antidepressant after nonresponse in adults with major depression: a systematic literature search and meta-analysis. J Clin Psychiatry [Internet]. 2018 Jan 1 [cited 2020 Dec 21];79(1):11–18. Available from: https://pubmed-ncbi-nlm-nih-gov.myaccess.library.utoronto.ca/27929611/
- Andreescu C, Mulsant BH, Houck PR, et al. Empirically derived decision trees for the treatment of late-life depression. Focus (Madison) [Internet]. 2009 Jan 1 [cited 2021 Jan 6];7(1):79–87. Available from: http://psychiatryonline.org/doi/abs/10.1176/foc.7.1.foc79
- Mulsant BH, Houck PR, Gildengers AG, et al. What is the optimal duration of a short-term antidepressant trial when treating geriatric depression? J Clin Psychopharmacol [Internet]. 2006 Apr [cited 2020 Dec 21];26(2):113–120. Available from: https://pubmed-ncbi-nlm-nih-gov.myaccess.library.utoronto.ca/16633138/
- Kudlow PA, McIntyre RS, Lam RW Early switching strategies in antidepressant non-responders: current evidence and future research directions [Internet]. 28, CNS Drugs. Springer International Publishing; 2014 [cited 2020 Dec 21]. 601–609. Available from: https://pubmed-ncbi-nlm-nih-gov.myaccess.library.utoronto.ca/24831418/
- Olgiati P, Serretti A, Souery D, et al. Early improvement and response to antidepressant medications in adults with major depressive disorder. Meta-analysis and study of a sample with treatment-resistant depression. J Affect Disord [Internet]. 2018 Feb 1 [cited 2020 Dec 21];227:777–786. Available from: https://pubmed-ncbi-nlm-nih-gov.myaccess.library.utoronto.ca/29254066/
- Wagner S, Engel A, Engelmann J, et al. Early improvement as a resilience signal predicting later remission to antidepressant treatment in patients with major depressive disorder: systematic review and meta-analysis [Internet]. 94, Journal of Psychiatric Research. Elsevier Ltd; 2017 [cited 2020 Dec 21]. 96–106. Available from: https://pubmed-ncbi-nlm-nih-gov.myaccess.library.utoronto.ca/28697423/
- Casey DE, Laubmeier KK, Marler SV, et al. Efficacy of adjunctive aripiprazole in major depressive disorder: a pooled response quartile analysis and the predictive value of week 2 early response. Prim Care Companion J Clin Psychiatry [Internet]. 2012 [cited 2020 Dec 21];14(3). Available from: https://pubmed-ncbi-nlm-nih-gov.myaccess.library.utoronto.ca/23106023/.
- Taylor RW, Marwood L, Greer B, et al. Predictors of response to augmentation treatment in patients with treatment-resistant depression: a systematic review [Internet]. 33, Journal of Psychopharmacology. SAGE Publications Ltd; 2019 [cited 2020 Dec 21]. 1323–1339. Available from: https://pubmed-ncbi-nlm-nih-gov.myaccess.library.utoronto.ca/31526204/
- Joel I, Begley AE, Mulsant BH, et al. Dynamic prediction of treatment response in late-life depression. Am J Geriatr Psychiatry [Internet]. 2014 [cited 2020 Dec 21];22(2):167–176. Available from: https://pubmed-ncbi-nlm-nih-gov.myaccess.library.utoronto.ca/23567441/
- Watanabe N, Maruo K, Imai H, et al. Predicting antidepressant response through early improvement of individual symptoms of depression incorporating baseline characteristics of patients: an individual patient data meta-analysis. J Psychiatr Res [Internet]. 2020 Jun 1 [cited 2020 Dec 21];125:85–90. Available from: https://pubmed-ncbi-nlm-nih-gov.myaccess.library.utoronto.ca/32247194/
- De Vries YA, Roest AM, Bos EH, et al., Predicting antidepressant response by monitoring early improvement of individual symptoms of depression: individual patient data meta-analysis. Br J Psychiatry [Internet]. 2019 Jan 1 [cited 2020 Dec 21];214(1):4–10. Available from: https://pubmed-ncbi-nlm-nih-gov.myaccess.library.utoronto.ca/29952277/
- Nakajima S, Uchida H, Suzuki T, et al. Is switching antidepressants following early nonresponse more beneficial in acute-phase treatment of depression?: a randomized open-label trial. Prog Neuro Psychopharmacol Biol Psychiatry [Internet]. 2011 Dec 1;35(8):1983–1989.
- Romera I, Pérez V, Menchón JM, et al. Early switch strategy in patients with major depressive disorder: a double-blind, randomized study. J Clin Psychopharmacol [Internet]. 2012Aug [cited 2020 Dec 21];32(4):479–486. Available from: https://pubmed-ncbi-nlm-nih-gov.myaccess.library.utoronto.ca/22722513/
- Bose A, Tsai J, Li D. Early non-response in patients with severe depression: escitalopram up-titration versus switch to duloxetine. Clin Drug Investig [Internet]. 2012 [cited 2020 Dec 21];32(6):373–385. Available from: https://pubmed-ncbi-nlm-nih-gov.myaccess.library.utoronto.ca/22559255/
- Tadić A, Wachtlin D, Berger M, et al. Randomized controlled study of early medication change for non-improvers to antidepressant therapy in major depression - The EMC trial. Eur Neuropsychopharmacol [Internet]. 2016 Apr 1 [cited 2020 Dec 21];26(4):705–716, Available from: https://pubmed-ncbi-nlm-nih-gov.myaccess.library.utoronto.ca/26899588/
- Patel K, Allen S, Haque MN, et al. Bupropion: a systematic review and meta-analysis of effectiveness as an antidepressant. Ther Adv Psychopharmacol [Internet]. 2016Apr [cited 2020 Dec 21]; 6(2):99–144. Available from: https://pubmed-ncbi-nlm-nih-gov.myaccess.library.utoronto.ca/27141292/
- Kessler DS, MacNeill SJ, Tallon D, et al. Mirtazapine added to SSRIs or SNRIs for treatment resistant depression in primary care: phase III randomised placebo controlled trial (MIR). BMJ [Internet]. 2018 [cited 2020 Dec 21];363. Available from: https://pubmed-ncbi-nlm-nih-gov.myaccess.library.utoronto.ca/30381374
- Nelson JC, Papakostas GI. Atypical antipsychotic augmentation in major depressive disorder: a meta-analysis of placebo-controlled randomized trials [Internet]. Am J Psychiatry. 2009 [cited 2020 Dec 21];166:(9)980–991. Available from: https://pubmed-ncbi-nlm-nih-gov.myaccess.library.utoronto.ca/19687129/
- Zhou X, Ravindran AV, Qin B, et al. Comparative efficacy, acceptability, and tolerability of augmentation agents in treatment-resistant depression: systematic review and network meta-analysis. J Clin Psychiatry [Internet]. 2015 Apr;76(4):e487–98. Available from: http://myaccess.library.utoronto.ca/login?url=https://search.proquest.com/docview/1715674350?accountid=14771
- Carter B, Strawbridge R, Husain MI, et al. Relative effectiveness of augmentation treatments for treatment-resistant depression: a systematic review and network meta-analysis [Internet]. 32, International Review of Psychiatry. Taylor and Francis Ltd; 2020 [cited 2020 Dec 21]. 477–490. Available from: https://pubmed-ncbi-nlm-nih-gov.myaccess.library.utoronto.ca/32498577/
- Papakostas GI, Salloum NC, Hock RS, et al. Efficacy of esketamine augmentation in major depressive disorder: a meta-analysis. J Clin Psychiatry [Internet]. 2020 Aug 1 [cited 2020 Dec 21];81(4). Available from: https://pubmed-ncbi-nlm-nih-gov.myaccess.library.utoronto.ca/32459407/
- Crossley NA, Bauer M. Acceleration and augmentation of antidepressants with lithium for depressive disorders: two meta-analyses of randomized, placebo-controlled trials. J Clin Psychiatry. 2007;68(6):935–940.
- Nelson JC, Baumann P, Delucchi K, et al. A systematic review and meta-analysis of lithium augmentation of tricyclic and second generation antidepressants in major depression [Internet]. 168, Journal of Affective Disorders. Elsevier B.V.; 2014 [cited 2020 Dec 21]. 269–275. Available from: https://pubmed-ncbi-nlm-nih-gov.myaccess.library.utoronto.ca/25069082/
- Bares M, Novak T, Kopecek M, et al. Is combined treatment more effective than switching to monotherapy in patients with resistant depression? A retrospective study [Internet]. researchgate.net. 2009 [cited 2020 Dec 21]. Available from: www.nel.edu
- Han C, Wang S, Seo H, et al., HJ-J of psychiatric, 2014 undefined. Aripiprazole augmentation, antidepressant combination or switching therapy in patients with major depressive disorder who are partial-or non-responsive to. Elsevier [Internet]. [cited 2020 Dec 21]; Available from: https://www.sciencedirect.com/science/article/pii/S0022395613003403?casa_token=P8RnkLt1tzIAAAAA:I2LIlfWXtbklnMCCc9r_rSNoYERAXs23oQe8fN5T204GaebtdrRRBiE1I1T-zMxdZ2n1KOrSiw
- Köhler S, Unger T, Hoffmann S, et al. Comparing augmentation with non-antidepressants over sticking to antidepressants after treatment failure in depression: a naturalistic study. Pharmacopsychiatry [Internet]. 2013 Mar;46(2):69–76. Available from: http://myaccess.library.utoronto.ca/login?url=https://search.proquest.com/docview/1370837112?accountid=14771
- Lam RW, Hossie H, Solomons K, Citalopram and Bupropion-SR: combining versus switching in patients with treatment-resistant depression. Artic J Clin Psychiatry [Internet]. 2004 [cited 2020 Dec 21];65(3):337–340. Available from: www.canbind.ca
- Papakostas GI, Petersen TJ, Green C, et al. A description of next-step switching versus augmentation practices for outpatients with treatment-resistant major depressive disorder enrolled in an academic specialty clinic. Ann Clin Psychiatry [Internet]. 2005Jul [cited 2020 Dec 21];17(3):161–165. Available from:: https://pubmed-ncbi-nlm-nih-gov.myaccess.library.utoronto.ca/16433058/.
- Xiao L, Zhu X, Gillespie A, et al. Effectiveness of mirtazapine as add-on to paroxetine v. paroxetine or mirtazapine monotherapy in patients with major depressive disorder with early non-response to paroxetine: a two-phase, multicentre, randomized, double-blind clinical trial. Psychol Med [Internet]. 2019 [cited 2020 Dec 21]; Available from: https://pubmed-ncbi-nlm-nih-gov.myaccess.library.utoronto.ca/31931894/
- Han C, Wang SM, Kwak KP, et al. Aripiprazole augmentation versus antidepressant switching for patients with major depressive disorder: a 6-week, randomized, rater-blinded,prospective study. J Psychiatr Res [Internet]. 2015 Jul 1 [cited 2020 Dec 21];66–67:84–94. Available from: https://pubmed-ncbi-nlm-nih-gov.myaccess.library.utoronto.ca/26013203/
- Fava M, Alpert J, Nierenberg A, et al. Double-blind study of high-dose fluoxetine versus lithium or desipramine augmentation of fluoxetine in partial responders and nonresponders to fluoxetine. J Clin Psychopharmacol [Internet]. 2002 [cited 2020 Dec 21];22(4):379–387. Available from: https://pubmed-ncbi-nlm-nih-gov.myaccess.library.utoronto.ca/12172337/
- Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry [Internet]. 2006 [cited 2020 Dec 21];163(11):1905–1917. Available from: https://pubmed-ncbi-nlm-nih-gov.myaccess.library.utoronto.ca/17074942/
- Rush AJ, Trivedi MH, Wisniewski SR, et al. Bupropion-SR, Sertraline, or Venlafaxine-XR after failure of SSRIs for depression. N Engl J Med [Internet]. 2006 Mar 23 [cited 2018 Jan 30];354(12):1231–1242. Available from: http://www.nejm.org/doi/abs/10.1056/NEJMoa052963
- Trivedi MH, Fava M, Wisniewski SR, et al. Medication augmentation after the failure of SSRIs for depression. N Engl J Med [Internet]. 2006 Mar 23;354(12):1243–1252.
- Fava MA, Rush AJ, Wisniewski SR. Comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D report. Am J Psychiatry [Internet]. 2006 Jul 1 [cited 2020 Dec 21];163(7):1161. Available from: https://pubmed-ncbi-nlm-nih-gov.myaccess.library.utoronto.ca/16816220/
- Nierenberg AA, Fava M, Trivedi MH, et al. A comparison of lithium and T3 augmentation following two failed medication treatments for depression: a STAR*D report. Am J Psychiatry [Internet]. 2006 [cited 2020 Dec 21];163(9):1519–1530. Available from: https://pubmed-ncbi-nlm-nih-gov.myaccess.library.utoronto.ca/16946176/
- McGrath PJ, Stewart JW, Fava M, et al. Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D report. Am J Psychiatry [Internet]. 2006 [cited 2020 Dec 21];163(9):1531–1541. Available from: https://pubmed-ncbi-nlm-nih-gov.myaccess.library.utoronto.ca/16946177/
- Mohamed S, Johnson GR, Chen P, et al. Effect of antidepressant switching vs augmentation on remission among patients with major depressive disorder unresponsive to antidepressant treatment. J Am Med Assoc [Internet]. 2017 Jul 11 [cited 2020 Dec 21];318(2):132–145. Available from: https://pubmed-ncbi-nlm-nih-gov.myaccess.library.utoronto.ca/28697253/
- Cristancho P, Lenard E, Lenze EJ, et al. Optimizing outcomes of treatment-resistant depression in older adults (OPTIMUM): study design and treatment characteristics of the first 396 participants randomized. Am J Geriatr Psychiatry [Internet]. 2019 Oct 1;27(10):1138–1152.
- Kato T, Furukawa TA, Mantani A, et al. Optimising first- and second-line treatment strategies for untreated major depressive disorder - the SUND study: a pragmatic, multi-centre, assessor-blinded randomised controlled trial. BMC Med [Internet]. 2018 Jul 11 [cited 2020 Dec 21];16(1). Available from: https://pubmed-ncbi-nlm-nih-gov.myaccess.library.utoronto.ca/29991347/
- Kim JM, Stewart R, Kang HJ, et al. Short and long-term treatment outcomes of stepwise psychopharmacotherapy based on early clinical decision in patients with depressive disorders. J Affect Disord [Internet]. 2020 Sep 1 [cited 2020 Dec 21];274:315–325. Available from: https://pubmed-ncbi-nlm-nih-gov.myaccess.library.utoronto.ca/32469822/
- Buchalter ELF, Oughli HA, Lenze EJ, et al. Predicting remission in late-life major depression: a clinical algorithm based upon past treatment history. J Clin Psychiatry [Internet]. 2019 [cited 2020 Dec 21];80(6). Available from: https://pubmed-ncbi-nlm-nih-gov.myaccess.library.utoronto.ca/31846575/
- Guo T, Xiang YT, Xiao L, et al. Measurement-based care versus standard care for major depression: a randomized controlled trial with blind raters. Am J Psychiatry [Internet]. 2015 Oct 1;172(10):1004–1013.
- Zeier Z, Carpenter LL, Kalin NH, et al. Clinical implementation of pharmacogenetic decision support tools for antidepressant drug prescribing. Am J Psychiatry [Internet]. 2018 Sep 1;175(9):873–886.